Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01720173 · ClinicalTrials.gov registry record · Phase 2
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01720173 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 30 participants.
The verdict
NCT01720173, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well dalantercept works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that has returned. Dalantercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Dalantercept may also stop the growth of tumor cells by blocking blood flow to the tumor.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Dalantercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-11-05 |
| Est. Completion | 2019-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01720173
The ClinicalTrials.gov registry entry for NCT01720173 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01720173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01720173 about?
NCT01720173 is a clinical study titled "Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer". This phase II trial studies the side effects and how well dalantercept works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that has returned. Dalantercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Da...
What is the current status of trial NCT01720173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2012-11-05. Estimated completion is 2019-02-19.
What interventions are being tested in trial NCT01720173?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Dalantercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT01720173?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.